### Pneumococcal Vaccine Timing—For Children

#### Age 2-23 Months

<table>
<thead>
<tr>
<th>Age:</th>
<th>Standard</th>
<th>PCV15 Vaxneuvance® or PCV20 Prevnar®</th>
<th>PCV15 Vaxneuvance® or PCV20 Prevnar®</th>
<th>PCV15 Vaxneuvance® or PCV20 Prevnar®</th>
<th>PCV15 Vaxneuvance® or PCV20 Prevnar®</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-15 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Catch-up: Healthy children 24-59 months: 1-4 doses PCV15 or PCV20 depending on age and timing of past doses.

### Age 2-18 Years With Underlying Condition(s)

- Children 2-18 years with any risk who have received all recommended doses before 6 years do not need further doses if they have received at least one dose of PCV20. If they have received PCV13 or PCV15, they should receive a dose of PCV20 OR PPSV23 (at least eight weeks after the prior dose of pneumococcal conjugate vaccine).
- Children 6-18 years with any risk who have not received any doses of PCV13, PCV15 or PCV20 should receive a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 >8 weeks later if not previously given.
- Children younger than 6 years of age should have received the standard or catch-up doses of PCV15 or PCV20. If PCV13 or PCV15 is used, follow with PPSV23 eight weeks later.
- Catch-up for Children 24-71 months with underlying conditions: 1-4 doses PCV15 or PCV20 depending on age and timing of past doses.

### Risk Categories:

#### Chronic conditions:
- Chronic heart disease (particularly failure or cyanotic disease)
- Chronic kidney disease
- Chronic liver disease
- Chronic lung disease (including moderate persistent or severe persistent asthma)
- Diabetes mellitus
- CSF leaks or Cochlear implants

#### Immunocompromise:
- On maintenance dialysis or nephrotic syndrome
- Asplenia or splenic dysfunction
- Immunodeficiency (including B- to T- cell deficiency, complement deficiency and phagocytic disorders excluding CGD)
- Diseases and conditions treated with immunosuppressive drugs or radiation treatments (Including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease)
- HIV infection
- Sickle cell disease or other hemoglobinopathies
- Solid organ transplant

1. When PPSV23 is used instead of PCV20 for children aged 2–18 years with an immunocompromising condition, either PCV20 or a second PPSV23 dose is recommended ≥5 years after the first PPSV23 dose.

For further details, see CDC’s [Pneumococcal Vaccine Recommendations](https://www.cdc.gov/vaccines/schedules/index.html).

California Department of Public Health, Immunization Branch  [www.EZIZ.org](http://www.EZIZ.org)